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Two different approaches to the solution synthesis of oligonucleo-
tides are compared. Both procedures use dimer synthons as build-
ing blocks to save time and to improve the final product yield and
quality. These strategies look quite promising due to their easy up-
scaling, providing an advantageous alternative to the well-establi-
shed solid-phase methods.
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INTRODUCTION
Synthesis of oligonucleotides is turning into a large scale production,
since they are increasingly demanded as new powerful drugs, as well as pro-
bes and primers in diagnostic kits.1 Synthesis of large quantities of these
nucleic acid derivatives is a prerequisite for their successful commercializa-
tion, especially as antisense drugs, which represent their widest field of ap-
plication.2
A simple and cost-efficient method is clearly the critical factor for a prof-
itable production of oligonucleotide-based therapeutics. On the other hand,
CROATICA CHEMICA ACTA CCACAA 74 (4) 779¿786 (2001)
* Author to whom correspondence should be addressed. (E-mail: bonora@dsch.univ.trieste.it)
modulation of gene expression by synthetic oligonucleotides is required for
specifically modified molecules. In particular, an increased nuclease resis-
tance is required, preserving the complexation capability toward comple-
mentary natural nucleic acid targets.3 Among the modifications reported to
date, the phosphorothioate analogues are the first compounds that reached
first the clinic, and, very recently, the market.4,5
The most diffused approach for the preparation of these biopolymers is
the solid supported synthesis based on the phosphoroamidite approach,
which requires quite a large amount of expensive syntons to drive each re-
action step to completion.6 Development of processes requiring fewer equiv-
alents of these reagents is obviously most desirable, and was recently inves-
tigated.7 However, despite a successful reduction of reagent consumption,
the solid-phase method, based on inert, insoluble supports, suffers from
some unavoidable drawbacks as a consequence of the heterogeneity of the
reaction. For this reason, it should be desirable to develop alternative pro-
cesses capable of being performed in homogeneous media. It is reasonable to
expect that a large upscaling of solution-based syntheses could be easily and
efficiently set up, following the general rules of the classical organic reac-
tions, allowing adequate planning of industrial production.
A possible solution for the disadvantages generated by the Merrifield-
like methods is the use of soluble polymeric supports that grant the homoge-
neity of the synthetic process and assure an easy intermediate purification
step through simple precipitation-and-filtration procedures.8 This approach,
named soluble polymer-assisted or liquid-phase synthesis, in analogy to the
solid-phase one, is particularly efficient for the oligonucleotide production,
even at a large scale. The support of choice is the poly(ethylene glycol) or
PEG, which offers unusual, but advantageous, physico-chemical properties.9
The synthetic method, called HELP or high efficiency liquid phase, adopts
the standard phosphoroamidite-based chemistry commonly employed in the
solid-phase procedures.10 Recently, the HELP approach was upscaled for the
millimolar-scale synthesis on a bench of phosphorothioate oligonucleotides
up to 20 monomers in length.11 As a further improvement, fully protected
dimers were used as synthons to reduce the number of coupling steps and
ameliorate the purity profile of the final crude material.12
Reese and coworkers have recently proposed an efficient, different solu-
tion to the above-mentioned drawbacks.13 Their approach uses phosphotri-
esters as building blocks in a classical solution synthesis. Following this
block condensation strategy, a quite large scale production of a fully thioate
octamer can be accomplished. Interestingly, the same octamer was also the
subject of an investigation aimed at the large-scale development of the
PEG-based supported synthesis.
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On these bases, it appeared worthwhile to compare the two synthetic
procedures in order to delineate the advantages and disadvantages of these
solution-based methods and highlight their useful properties compared to
the well-founded solid-phase procedures.
EXPERIMENTAL
The synthesis of phosphoramidite dimers was performed as described.12 The
HELP protocol was easily transferred to the dimeric synthons following the basic
procedure,10 and details of the experimental procedures are reported.11 All the exper-
imental procedures required for the solution synthesis of an oligonucleotide via
phosphothiotriester intermediates are also extensively described.13 Chromatogra-
phic analyses and purifications, as well as spectrophotometric and NMR data, are
reported in the references.
RESULTS AND DISCUSSION
The common feature of the two synthetic strategies here examined is the
use of pre-built dimeric synthons for the assembling of the same fully thio-
ate sequence, that is d(T2G4T2).
In the case of phosphoramidite-based units, this procedure derives from
the problem commonly experienced in automated synthesis via monomeric
units including formation of a population of deleted sequences. This pheno-
menon is mainly due to less-than-quantitative coupling yields, incomplete
intermediate reactions as well as defects during the work-up protocol. Dur-
ing the final purification procedure, a rather poor efficiency of the resolution
of (n-1)mer and nmer is observed. Moreover, side reactions during sulfu-
rization steps must also be considered, introduced the presence of unwanted
phosphodiester linkages. If all these steps are the main cause of the reduced
homogeneity of the final crude product, the blockmer coupling strategy
could be a way of decreasing the number of the related side products by re-
ducing the number of the overall intermediate steps required. However, it is
obvious that the use of dimers will reduce the overalls steps of the suppor-
ted synthesis, but it will require a more time-demanding procedure for the
preliminary preparation of the synthons needed. In our case, the 5'-DMT-
protected, 3'-O-2-cyanoethyl-N-diisopropylphosphoramidite dimeric units
were successfully employed following the standard HELP-based oligouncleo-
tide synthesis, without any problem of solubility or removal of the excess
from the reaction mixture. Addition of 3 equivalents of amidites, with re-
gard to the PEG-bound functional groups, in the presence of 1H-tetrazole,
gave very satisfactory coupling yields, as shown in Table I. Moreover, the re-
duced number of individual steps increased the amount of the product re-
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covered, as shown in Table II. In fact, during the liquid-phase synthesis,
precipitation of the PEG-bound product is required after each step, followed
by its filtration to remove all soluble by-products and the residual excess of
reagents. During these operations, some loss of material as a function of the
solubility product of the growing oligonucleotide bound to PEG is clearly
present, even if low.
The scheme of the overall process is reported in Scheme 1.
Reese et al. proposed a different strategy for the application of a solution
procedure based on phosphotriester chemistry. This chemistry is tradition-
ally adopted for the classical solution synthesis of oligonucleotides because
of the more advantageous stability and solubility properties of synthons.
The key reaction involves coupling between a protected dimer terminating
in a 3'-(S-2-cyanoethyl)phosphorothioate and a protected dimer terminating
in a free 5'-OH function. In this case, the coupling reaction is promoted by
an activating mixture (mesitylene-2-sulfonyl chloride and 3-nitro-1,2,4-1H-
triazole). The main difference in this case is the use of a blockmer of increa-
sed size, as the chain is growing, as depicted in Scheme 2. It is quite obvious
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TABLE I
Single step and average yields, deduced from DMT absorption,
of 8mer phosphorothioate synthesized on MPEG (Mr = 5,000)
Reaction step Yield / %
MPEG-OH + d(T) dimer 100
MPEG-2mer + d(G) dimer 99
MPEG-4mer + d(G) dimer 99
MPEG-6mer + d(T) dimer 98
Average step yield value 96.5
TABLE II
Expected and recovered quantity of MPEG-oligomers, fully protected, starting
from 5.0 g of MPEG (Mr = 5,000) MPEG = monomethoxypoly(ethylene glycol)
Reaction step Expected amount / g Recovered amount / g
MPEG-OH + d(T) dimer 6.00 5.56
MPEG-2mer + d(G) dimer 6.94 6.19
MPEG-4mer + d(G) dimer 7.87 6.73
MPEG-6mer + d(T) dimer 8.62 7.17
that when, as for the 8mer under study, a symmetrical sequence is con-
structed, it is in principle possible to save a further, intermediate coupling
step by using the same tetramer synthesized during the process. On the
other hand, the general features of the liquid-phase synthesis are common
to all the supported procedures and, consequently, all of the intermediate
sequences cannot be used as new synthons in the overall synthesis plan-
ning. However, in this case, both tetramers are separately synthesized
since, as described in Scheme 2, the two final building blocks have the same
nucleotide composition, but different 5'- and 3'-protecting groups. In fact,
the sequence is self-complementary and consequently the two tetramers
have the same order of nucleotides, but a different direction. Moreover, in
the phosphotriester method, the two fully protected starting dimers need to
be further reacted to remove the terminal protecting groups and introduce
the S-protected, phosphothioate moiety. This must be taken into account
when the overall yields given by the two procedures are compared. Interest-
ingly, from the IE HPLC profile of the crude oligonucleotide obtained from
the liquid-phase method, it can be estimated that at least 35% of the mix-
ture is on charge of the pure product (data not shown). This value is almost
coincident with the overall yield obtained from Reese’s procedure, as dedu-
ced from the data reported in Table III.
The main advantage of phosphotriesters is certainly a highly reduced
excess (1.2–1.3 fold) required during each coupling of 3'-phosphoroester.
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Scheme 1. Scheme of the large-scale synthesis of the 8mer phosphorothioate using
phosphoramidite dimeric synthons in the liquid-phase procedure.
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TABLE III
Reaction yields and product quantity from the phosphotriester-based
process (calculated)13












step D + B = E 69 1.03
2
nd
step A + C = F 80 0.82
3
rd
step E + F = 8mer 65 0.87
Scheme 2. Scheme of the large-scale synthesis of the 8mer phosphorothioate using
phosphotriester dimeric synthons in the classical solution procedure.
This will save expensive reagents that can be hardly recovered, but it must
be underlined that an increased excess will push yields to higher values and
must be avoided since it can hamper all the intermediate purification steps.
In fact, the main difference from the classical solution processes and sup-
ported syntheses is the requirement, for the former, of laborious two-solvent
extractions and chromatographic purifications, instead of handy precipita-
tion-and-filtrations. From the reported data, it can be easily calculated that
to obtain 1.0 g of pure 8mer, the same amount of starting dimeric blocks
must be utilized, that is, about 4.0 grams.
Another point is the solubility property of the larger oligonucleotide
when used as a building block. It is well known that increasing the chain
length will reduce the solubility properties of the oligonucleotide inside the
reaction media, with a concomitant reduction of the coupling step effi-
ciency.14 The lipophilicity of the fully protected oligonucleotide can be en-
hanced through the introduction of proper protecting moieties, however the
synthesis of the long oligonucleotide chain, up to 20mers, can be hardly de-
vised in a classical solution procedure. On the other hand, the use of solu-
ble, solubilising supports, as PEG, can eliminate this drawback since the
larger polymeric supporting unit will drive the solubility properties of the
growing oligonucleotide, if its size is properly chosen at the beginning of the
synthesis. Unfortunately, the longer the oligonucleotide to be prepared, the
larger is the PEG to be used; consequently, the amount of the derivative pro-
duced is proportionally reduced, since no more than two anchoring func-
tional groups are present in a linear, commercial PEG. Moreover, the use of
PEG, as well as of any other support, adds a further step for its final re-
moval, and, more important, proper recovery and recycling required for eco-
nomical reasons.
In conclusion, both the described solution syntheses appear to be supe-
rior to the solid-phase method in the large-scale preparation of oligonucleo-
tide and oligonucleotide phosphorothioates of moderate size, since the
upscaling of the organic solution syntheses is properly designable without
special apparatus. On the other hand, it is well known that the Merrifield-
like procedures can be readily automated, allowing very fast and efficient
coupling reactions along with a more friendly operativity, which does not de-
mand any special skill. Large scale synthesizers operating on an up to 0.2
mol scale are currently available, but it is quite hard to imagine a synthe-
sizer that could furnish all the quantity of the oligonucleotide derivative
needed for the market in one, or a few, single batches.
As recently reported, we agree that »further oligonucleotide manufactur-
ing processes are likely to integrate a variety of options, ultimately deliver-
ing safe and cost-effective methods for large-scale production of oligonucleo-
tides«.15
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Sinteza fosfortioat-oligonukleotida u otopini na veliko: usporedba
fosforamidilnog i fosfortriesterskog dimernog pristupa
Gian Maria Bonora, Simone Zaramella i Vasulinga Ravikumar
Opisana su i uspore|ena dva razli~ita pristupa sintezi oligonukleotida u otopini.
Oba pristupa zasnivaju se na primjeni sinteze dimera kao gra|evnih blokova, ~ime
se posti`e u{teda u vremenu, te pobolj{ano iskori{tenje i kvaliteta kona~nog pro-
dukta. Opisanim se strategijama lako mo`e pove}ati mjerilo, {to je ujedno i njihova
prednost pred dobro poznatim (uobi~ajenim) metodama sinteze u krutoj fazi.
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